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Every three minutes, someone in the United States is diagnosed with blood 
cancer, the most common of which being Leukemia, or the cancer of white blood cells 
[1]. Distinguishing between healthy white blood cells and leukemia cells has proven to be 
difficult because the physical and visual similarities between the two. Unlike tumorous 
cancers, leukemia cells are much more difficult to distinguish and characterize in a 
clinical setting because of the physiologic nature of the disease. Current diagnostic 
methods like flow cytometry are known to be time-consuming and costly, creating a 
crucial need to more effectively identify white blood cells (WBCs) from leukemic cells. 
The purpose of this study is to use biomechanical markers to characterize the 
distinct properties of healthy WBC’s and the different types of leukemia. By measuring 
multiple biomechanical characteristics of each type of cell, each cell type will be able to 
be narrowed down into a cluster that is representative of the biomechanical characteristics 
distinctive to that cell type. As we know, it is difficult to distinguish differences in 
leukemic and healthy WBC’s by a factor of size alone, but adding additional biophysical 
parameters may lead to improved identification of the pathological condition. Our 
proposal intends on using four distinct biomechanical parameters to complete our 
analysis: size, elastic modulus, and both slow and quick viscoelastic response time 
constants, tau1 and tau2. It has been shown that distinct differences in these specific 
characteristics do exist between healthy and cancerous WBC’s [2,3], so by analyzing 
these parameters against each other, we hope to gain a more complete understanding of 












 Leukemia is a blood disorder that affects over one million people in the United 
States alone. Leukemia is a cancer of white blood cells, where genetic mutations cause 
unregulated cell cycle control and affect the normal division and proliferation of affected 
cells. The leukemic cells do not undergo normal cell apoptosis when damaged, thus 
accumulating and overcrowding the normal blood cells [1].  Because of the wide variety 
of white blood cells (WBC’s) in the human body, leukemia is very different from other 
cancers in the breadth of cases, affecting patients anywhere from young children to the 
elderly. Also unlike most cancers, age, race, and lifestyle habits, and background do not 
exempt anyone from being at risk for the disease, and accounts for over 50,000 new 
cancer cases annually [1]. Because it does not form tumors, leukemia is not considered 
“metastatic”, but it does form dangerous accumulations in the lymph nodes, spleen, and 
brain [1].   
White Blood Cell Physiology and Leukemia Typing 
When considering typing leukemia, the physiologic origin of the affected cells is 
the distinguishing characteristic between the types. Depending on the origin, one of four 
main types may arise, and each types carries similar characteristics and symptoms. In the 
pluripotent form, a blood stem cell may give rise to all components of blood cells, 
including all white and red cells, and platelets [1]. A blood stem cell further differentiates 
into a myeloid stem cell (MSC), or a lymphoid stem cell (LSC). As the same suggests, an 
MSC originates in the bone marrow, while an LSC will originate in the lymph nodes. The 
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MSCs and LSCs further differentiate into myeloblasts and lymphoblasts, respectively 
(Figure 1). Each of these two cells can become cancerous, forming either myelogenous or 
lymphoblastic leukemia. Each of these morphologies give rise to either a chronic or acute 
cancer. Acute leukemias have a rapid onset, characterized by abnormally high 
accumulations of mutated cells and a quick deficiency in normal lymphoblast 
functioning. Symptoms may include fatigue, bruising, and extreme immunosuppression 
and susceptibility to disease [1]. Chronic leukemias, however, progress slowly, and the 
cancerous cells function almost as well as their healthy WBC counterparts. Abnormal 
blood tests may be preliminary indicators of chronic leukemia, and patients may not 
know they are infected due to lack of noticeable symptoms [1]. The combination of the 
cellular origin and the onset of the disease gives rise to the four main leukemia types: 
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic 
Myeloid Leukemia (CML), and Chronic Lymphoblastic Leukemia (CLL). AML accounts 
for 36% of all new cases of leukemia, but is by far the most lethal with a bleak 25.4% 5-
year survival rate [1,4]. ALL accounts for over 75% of all new cases in children, and the 
risk of contraction is highest amongst children under the age of 5 [1,4]. CML has a 
relatively low 5-year survival rate of 59.9%, and accounts for 11% of all new cases [4]. 
CLL is relatively common, accounting for 30% of new cases, but carries a relatively high 
survival rate of 83.5% [4]. This study chooses to investigate three of the four main cancer 
types: ALL (childhood leukemia), AML (the most lethal), and CML (the most common 
in elderly patients) [1,4]. Jurkat was the immortalized model cell line for ALL, HL60 was 
the model for AML, and K562 was the model for CML. These cell types are commonly 
seen throughout the literature. Neutrophils were chosen for the healthy myeloid cell 
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model, which make up 80-90% [5] of myeloid cells. Lymphocytes were chosen as the 
lymphoblastic cell model. 
Diagnostics and Treatment 
 When someone is thought to have leukemia, a series of tests are performed to 
confirm the diagnosis, determine the type of leukemia present, and develop a prognosis 
and treatment plan. Blood tests are used in conjunction with bone marrow tests to 
develop a complete diagnosis, starting with a complete blood count (CBC) [5]. Blood is 
taken form a peripheral vein and the amount of each type of WBC, along with RBCs and 
platelets, are determined. Depending on the type of leukemia present, certain white blood 
cells will be uncharacteristically high or low. A peripheral blood smear may be 
completed, which involves placing a drop of blood of a microscope slide for viewing [5]. 
Morphological changes in WBCs are noted. If blood tests cannot rule out leukemia, a 
bone marrow biopsy is performed. In a bone marrow collection procedure, a local 
anesthetic is given, and a small needle is inserted into the back of the hip. The first 
sample collected is usually done through a bone marrow aspiration, where a small 
amount of liquid bone marrow is expunged though a syringe. If needed, a bone marrow 
biopsy is performed, in which a larger needle is used to extract larger, solid amounts of 
marrow. Even with properly applied local anesthetic, most patients report feeling pain 
upon the biopsy needle entering the hip bone.  
Indications of diseased-state cells 
 Historically, biochemical markers have been utilized to determine cancerous 
potential of cells. Gene expression or suppression have been widely studied as indicators 
of cancer, as well as different chemical markers present on the surface of cells. More 
recently, however, the mechanical properties of cells have given researchers more of an 
insight into how disease affects cellular structure and function, and perhaps even using it 
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as a marker to predict diseased versus healthy state cells. White blood cells and leukemia 
cells have been of particular interest in the field of cellular biomechanics, as it is 
presumed that the mechanics of the two morphologies differ [2]. Researchers have used 
optical trapping techniques to measure the mechanical properties of neutrophils [6]. More 
specifically, studies were conducted to measure neutrophil protrusional stiffness, defined 
by the loading rate in relation to stiffness. The dependence of these two factors indicated 
a viscoelastic character of WBCs [6], and assumptively their cancerous counterparts. 
Studies have shown that the relative stiffnesses of WBC morphologies and cancer lines 
are significantly different from each other, and even different from their own cell type at 
different phases of differentiation [7].  In other studies, the Atomic Force Microscope 
(AFM) proved to be a useful tool for measuring components of blood, including both 





MATERIALS AND METHODS 
Cancer Cell Culture 
 Jurkat cells were cultured in 20% Fetal Bovine Serum (FBS), 1% Pennicilin-
Streptomycin (Pen-Strep), and 79% Roswell Park Memorial Institute (RPMI) media base. 
K562 cells were cultured in 10% FBS, 1% Pen-Strep, and 89% Dulbecco’s Modified 
Eagle’s Medium. HL60 cells were cultured in 20% FBS, 1% Pen-Strep, and 79% DMEM 
media base. Media materials were obtained from Sigma Aldrich, and were stored in a 
culture refrigerator. Immortalized cell lines were obtained from American Tissue and 
Cell Culture. All cell lines were grown in suspension. Cells were passed every 2-3 days, 
and stored in an incubator at 37 degrees Celsius.  
Healthy Cell Isolation 
 Healthy white blood cells (WBCs) were harvested from samples of healthy donor 
blood. Donor blood was taken in 3 ml samples via venipuncture of a peripheral vein.  
Blood was stored in a blood collection tube coated with EDTA/anticoagulant. Whole 
blood was immediately centrifuged with a red blood cell lysis buffer in a concentration of 
25%. After 10 minutes of centrifugation, DPBS was added to stop the RBC lysis reaction, 
aspirate was collected, and remaining WBC pellet was again centrifuged with red blood 
cell lysis buffer. The samples were then placed in a centrifuge tube with 3 ml of DPBS, 
and stored in an incubator at 37 degrees Celsius until plating. 
6 
 
Cell Plating and Preparation 
 Both healthy and cancerous cells were divided into concentration of 200,000 
cells/mL and stored at 37 degrees Celsius. A fluorodish was plated with 25 microliters of 
Poly-L-Lysine (PLL) and PLL was spread over the surface. The fluorodish was placed in 
a sterile cell culture cabinet for five minutes to allow for maximal binding of PLL. Cells 
were then plated directly onto the fluorodish, and stored at 37 degrees Celsius for ten 
minutes to allow for maximal electrochemical adherence of cells to the surface of the 
fluorodish. Cells were then viewed under an optical microscope to confirm adherence. 
Fluorodishes were obtained from World Precision Instruments. 
Atomic Force Microscopy 
 An MFP-3D Atomic Force Microscope (AFM) from Asylum Research was used 
to take measurements on Elastic Modulus and Viscoelasticity. Silicon Nitride cantilevers 
were placed onto the AFM head and secured with a magnetic Phillips Head Screwdriver. 
The AFM head was then placed over a fluorodish containing 3 ml of deionized water, and 
cantilevers were then visualized in both a top-view and bottom-view camera. A laser was 
focused onto the tip of the cantilever at a maximal x-and-y position, and the cantilevers 
were engaged at a -13 degree angle from the horizon. Once the cantilevers were in 
contact in glass, a single force measurement was taken, and the spring constant and 
virtual deflection line were calibrated using Asylum Research software. The deflection 
was set to zero. Thermal capture was utilized to account for thermal noise and 
intermolecular movement experienced by the cantilever due to the surroundings of the 
room. The fluorodish was then removed, and replaced with the fluorodish with cells to be 
7 
 
measured. The cantilever would then indent the surface of a cell with a specified force 
distance, trigger point, and downwards velocity. Once in contact, the cantilever would 
record a graph of cantilever deflection vs. time and force vs. time, collecting elastic data. 
The cantilever would then slowly retract from the cell for a specified amount of dwell 
time, and record viscous data. A Nikon microscope was then used to take an image from 
the bottom-side camera of the cell post-measurement. Measurements were repeated until 
ideal sample size was reached.  
Analysis 
 Once experimentation was complete, the force vs. time curves were pulled from 
the Asylum Research file and were fitted with a double exponential curve fitting 
algorithm to find best fit of elastic modulus, and tau1 and tau2. Values that were not able 
to be understood by the Igor curve fitting algorithm were not recorded, and testing was 
repeated until sample size was reached. Images were analyzed with ImageJ to match the 
known diameter of the cantilever to a pixel ratio, and cell size was then recorded. Data 
was saved in Microsoft excel sheets, and box plots, 2D, and 3D plots were generated 
using Matlab.  
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CHAPTER 3  
RESULTS  
Elastic Modulus 
 Single force stiffness measurements were used to find the Elastic Modulus of 
Jurkat, HL60, K562, neutrophils, and lymphocytes. Jurkat showed an elastic modulus of 
118.52 +/- 134.73.  HL60 showed an elastic modulus of 372.92 +/- 328.63.  K562 
showed an elastic modulus of 375.54 +/- 265.88.  Isolated neutrophils showed an elastic 
modulus of 199.49 +/- 175.49.  Lymphocytes showed an elastic modulus of 601.33 +/- 
386.19. These values are consistent with previous studies [2,3]. 
 
Viscoelasticity 
 Single force stiffness measurements with a 5 second dwell time obtained a 
retraction curve to measure viscous response in a quick-relaxation parameter (tau1) and a 
slow-response parameter (tau2). Jurkat gave a tau1 of .1676 +/- .0593 and a tau2 of 
1.8847 +/- 1.1794. HL60 gave a tau1 of .2001 +/- .1761 and a tau2 of 1.993 +/- 1.5173. 
K562 gave a tau1 of .1725 +/- .0744 and a tau2 of 2.246 +/- 2.0209. Isolated neutrophils 
gave a tau1 of .1658 +/- .061 and a tau2 of 1.8756 +/- .9405. Lymphocytes gave a tau1 of 




 Cell size was determined with relative pixel-to-unit measurement analysis for 
each cell. Jurkat showed a cell diameter of 11.764 +/- 1.3847.  HL60 showed a cell 
diameter of 14.974 +/- 3.6134.  K562 showed a cell diameter of 16.025 +/- 25534.  
Neutrophils showed a cell diameter of 13.267 +/- 2.2266.  Lymphocytes showed a cell 





 An analysis of these values in Matlab yielded differentiation 2-and-3-D plots 
(Figures 2-8). Lymphocytes and Jurkat cells showed particular separation on the axes of 
cell diameter and elastic modulus, and somewhat on the tau1 axis (Figure 6). HL60, 
K562, and neutrophils showed particular separation on the axes of tau1 and cell diameter 
(Figure 4). Separation differentials for all cell types on the axes of cell diameter, elastic 
modulus, and tau1 can be seen in Figure 5. 
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CHAPTER 4  
DISCUSSION 
AML and CML vs. Myeloid Cells 
 When comparing AML leukemia with its healthy WBC counterpart, HL60 
mechanical parameters were compared against healthy myeloid cells (neutrophils). 
Neutrophils were softer than both HL60 and K562. Neutrophils also showed smaller 
quick- and slow-relaxation time constants. K562 cells had significantly higher tau1 and 
tau2 values than both other cell types (Figure 2). Both cancerous cells were larger than 
the healthy myeloid cells, and K562 cells were significantly larger than both types. 
Neutrophils were smaller and softer, which may seem counterintuitive; this suggests that 
if the cytoskeletal area is equal in amount and neutrophils experience a lower cytoskeletal 
density, the cancer morphologies experience cytoskeletal stiffening. If this is not the case, 
then cytoskeletal features may be diminished altogether, or another organelle may 
contributing to cellular stiffness.  
 
ALL vs. Lymphatic Cells 
 When comparing ALL leukemia with its healthy cell counterpart, Jurkat 
mechanical parameters were analyzed against lymphocytes. In contrast to the 
myelogenous leukemias, Jurkat was drastically softer than its healthy WBC counterpart. 
Jurkat and lymphocytes had virtually indistinguishable quick-response viscoelasticity 
time constants, however, and very similar slow-response constants. This is certainly 
curious; this suggests that viscosity may not be the driving mechanical property 
physiologically for this morphology; rather, stiffness plays a key role. As was the case in 
the myelogenous leukemias, the Jurkat cells were significantly smaller than their healthy 




Cancer Cell Types 
 Elastic modulus values amongst the cancer types were relatively consistent. They 
were much lower than lymphocytic cells, all though a hierarchy did arise; K562 were 
stiffest, followed by HL60, and finally the lymphocytic cancer Jurkat. The same trend 
was seen in cell size, following the same order with the same three cell types. 
Viscoelastic time constants for all three types were relatively similar. Tau2 followed the 
same trend as size and stiffness. The three of these in conjunction with each other may 
prove to lend a key role in 3-dimensional differentiation, or perhaps even 2-D. (Figure 4). 
  
Limitations 
 Limitations of the study center around the subjective nature of comparative 
analysis. While absolute values for each type of cancer and WBC cell type are ideal, 
deviations in physiologic samples cause wide ranges of values for all mechanical 
parameters. In the cancerous morphologies, size seems to be subject to larger deviations 
(particularly in the K562 cell line). In healthy cells, mechanical properties seem to vary 
more. Cells at different phases of proliferation, differentiation, and cell cycle all may 
account for variances and irregularities. Because of these larger deviations, clustering 
analysis is more complex and subject to error. It is certainly possible on a 2-Dimensional 
and even 3-Dimensional axis plot to have overlap of cell types. Probability of a cell being 
a certain type will never reach 1.00; rather, a probability may more usefully be 
determined of which cell type a certain sample is not. While certain trends are evident 
just by visualizing the plots generated, a more sophisticated algorithm may lend in 




CONCLUSIONS AND APPLICATIONS 
Typing Library and Microfluidics 
 In the future, if a library was compiled that gave each type of leukemia cell a 
unique mechanical profile, one could test the mechanical properties of a person’s WBCs 
for diagnostic purposes. Similar to a CBC blood test or a peripheral blood smear, a single 
sample of blood could be collected and analyzed. Unlike the two former tests, if a reliable 
library was developed, there may not be further need for a bone marrow biopsy 
procedure.  
 Utilizing different microfluidic platforms could yield pure populations of cancer 
cells. Microfluidic chips used in cellular separation would be able to filter out cancer 
morphologies from the rest of the blood, giving clinicians a pure population of cells to 
run more specialized tests on for diagnostic purposes.  
 
Cellular Staining 
 It is well documented that different compartments of the cell exhibit different 
mechanical properties [5,6].  The main organelle associated with structural rearrangement 
is the cytoskeleton, composed of many varying filament types. Many of these 
rearrangement processes cause conformational changes of the cell, and it is thought that 
they may play a role in the mechanical properties of cells. Numerous chemical stains 
exist to allow visualization of the cytoskeleton under fluorescent light. By staining the 
cytoskeleton and then measuring mechanical properties, one may be able to draw 
correlations between the physical arrangement of the structural components of the cell 
and cellular stiffness. Rearrangement of the cytoskeleton after perturbation may be of 




Chemotherapy and Drug Delivery 
 The addition of chemotherapy and other cancer-fighting drugs could be of interest 
when studying mechanical properties. Many cellular processes, including proliferation 
and apoptosis, can be mediated or influenced by mechanical properties, as well as cause 
changes in the cellular mechanics themselves. The addition of chemotherapy agents and 
other drugs before measurement with AFM could shed light on the mechanical properties 









DESCRIPTION OF DEFAULT SUBHEADING SCHEME 
 
Figure 1: White Blood Cell Differentation. Taken from cancer.gov. Figure shows the 
progression of cells from stem cells to blasts to final cell type. 
 
Elastic Moduli of all Cell Types 
 
Figure 2: Elastic Moduli of all Cell Types. Box and whisker plots of each cell type is 




Figure 3: Elastic Modulus vs. Cell Diameter. All cell types were plotted with different 




Figure 4: Cell Diameter vs. Elastic Modulus vs. tau1. All cell types were plotted with 
different markers, with tau1 on the z-axis, elastic modulus on the y-axis and cell diameter 




Figure 5: Cell Diameter vs. Elastic Modulus vs. tau1 for Myeloid Morphologies. 
Neutrophils, HL 60 and K562 cell types were plotted with different markers, with tau1 on 




Figure 6: Cell Diamter vs. Elastic Modulus vs. tau1 for Lymphocytic Morpholoies. 
Lymphocytes and Jurkat cell types were plotted with different markers, with tau1 on the 





Figure 7: Elastic Modulus vs. Cell Diameter for Neutrophils and HL60 Cells. 
Neutrophils and HL60 cell types were plotted with different markers, with elastic 




Figure 8: Elastic Modulus vs. Cell Diameter for Neutrophils and K562 Cells. 
Neutrophils and K562 cell types were plotted with different markers, with elastic 
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